U.S. Markets open in 8 hrs 8 mins

The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $76.61, marking a -0.48% move from the previous day.

For Immediate Release

Chicago, IL – November 6, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeKeryx Biopharmaceuticals, Inc. KERX, Bristol-Myers Squibb Company BMY, Dynavax Technologies Corporation DVAX, Heron Therapeutics, Inc. HRTX and Ultragenyx Pharmaceutical Inc. RARE.

Here are highlights from Friday’s Analyst Blog:

5 Biotech/Pharma Stocks with Key FDA Catalysts

The FDA, which approved 22 novel drugs last year, has given its approval to 35 drugs so far in 2017 including a key approval in October – Gilead’s Yescarta, a cell-based gene therapy for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. This makes Yescarta the second gene therapy to gain FDA approval, the first being Novartis’ Kymriah. Kymriah was approved in late August 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (“ALL”).

Other key approvals this year include Lilly’s Verzenio (advanced or metastatic breast cancer), Gilead’s Vosevi (hepatitis C virus), Puma’s Nerlynx (to reduce the risk of breast cancer returning), J&J’s Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sanofi’s Kevzara (rheumatoid arthritis), Roche’s multiple sclerosis treatment, Ocrevus, Regeneron and Sanofi’s eczema treatment, Dupixent, Tesaro’s PARP inhibitor, Zejula, and BioMarin’s Brineura (treatment of a specific form of Batten disease) among others. Quite a few of these drugs have blockbuster potential.

With the drug development process being lengthy and time-consuming and requiring the utilization of a lot of funds and resources, key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts. Here is a look at a few important regulatory events scheduled for the month of November.

Keryx’s Auryxia Under Review for Label Expansion: Keryx Biopharmaceuticals, Inc., which is focused on developing medicines for renal disease, is seeking FDA approval for the label expansion of Auryxia. The company is looking to get Auryxia approved for the treatment of patients with iron deficiency anemia and non-dialysis dependent chronic kidney disease (“CKD”). A decision should be out on November 6. Approval for this indication would expand the patient population for Auryxia which brought in sales of $24.6 million in the first half of 2017.

Keryx’s shares are up 2.9% year to date, compared to the industry’s 2.7% rally.

Label Expansion for Bristol-Myers’s Sprycel? Bristol-Myers Squibb Company is looking to expand the label of its blockbuster drug, Sprycel, so that it can be used for the treatment of children with Ph+ chronic phase (“CP”) chronic myeloid leukemia (“CML”). The company is also seeking approval for a powder for oral suspension (“PFOS”) formulation of Sprycel. A response from the FDA for the regulatory application, which is under priority review, is expected on November 9. Label expansion should boost Sprycel sales further - the drug brought in sales of $1.5 billion in the first nine months of 2017.

Bristol-Myers’s shares are up 6.4% year to date, compared to the industry’s 15.1% rally.

Bristol-Myers is a Zacks Rank #3 (Hold) stock - you can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Will It Be Third Time Lucky for Dynavax’s Heplisav-B? Dynavax Technologies Corporation is awaiting a response from the FDA for its hepatitis B vaccine, Heplisav-B, this month. Earlier this year, the vaccine had got a favorable recommendation (12-1) from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). With the positive vote, expectations were high that the company would finally gain approval for the vaccine which had previously received two complete response letters (one in November 2016 and the other in February 2013). However, the FDA action date of August 10 was pushed out by three months with the agency asking for more detailed information about the company's proposed post-marketing study for the vaccine.

With the additional information being considered a major amendment to the Biologics License Application (“BLA”), the FDA is expected to give its response regarding the approval status of the vaccine by November 10. Approval would allow Dynavax to go ahead with its plans to launch the vaccine early next year.

Dynavax’s shares are up 431.7% year to date, compared to the industry’s 2.7% rally.

Heron’s Cinvanti Under Review for CINV: Commercial-stage biotech company, Heron Therapeutics, Inc. is awaiting a decision from the FDA for Cinvanti, which is under review for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). Approval would strengthen Heron’s CINV franchise by adding a second, complementary therapeutic agent. The FDA is expected to give its decision on November 12.

Heron’s shares are up 18.7% year to date while the industry recorded a decline of 0.9%.

Will Ultragenyx Gain FDA Approval for Its First Product? Clinical-stage biopharmaceutical company, Ultragenyx Pharmaceutical Inc. has an FDA action date coming up this month for vestronidase alpha or rhGUS which is under review for mucopolysaccharidosis 7 (MPS 7) also known as Sly syndrome. About 200 patients across the world are afflicted by this disease, which is one of the rarest forms of MPS. Currently, there are no approved treatments for MPS 7. Approval for rhGUS on November 16 would transform Ultragenyx into a commercial-stage company.

Ultragenyx’s shares are down 31.8% year to date, compared to the industry’s 2.7% rally.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year.See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report
Keryx Biopharmaceuticals, Inc. (KERX) : Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research